Jupiter Neurosciences (JUNS) vs. Its Rivals Financial Review

Jupiter Neurosciences (NASDAQ:JUNS) is one of 247 public companies in the “MED – DRUGS” industry, but how does it weigh in compared to its peers? We will compare Jupiter Neurosciences to similar companies based on the strength of its earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Jupiter Neurosciences and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1	0	0	0	1.00
Jupiter Neurosciences Competitors	2922	4076	10364	476	2.47

As a group, “MED – DRUGS” companies have a potential upside of 122.68%. Given Jupiter Neurosciences’ peers stronger consensus rating and higher probable upside, analysts clearly believe Jupiter Neurosciences has less favorable growth aspects than its peers.

Volatility & Risk

Jupiter Neurosciences has a beta of 2.16, suggesting that its stock price is 116% more volatile than the S&P 500. Comparatively, Jupiter Neurosciences’ peers have a beta of -0.49, suggesting that their average stock price is 149% less volatile than the S&P 500.

Valuation and Earnings

This table compares Jupiter Neurosciences and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jupiter Neurosciences	$20,000.00	-$8.65 million	-1.39
Jupiter Neurosciences Competitors	$1.18 billion	$107.93 million	-4.34

Jupiter Neurosciences’ peers have higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

44.1% of shares of all “MED – DRUGS” companies are held by institutional investors. 50.8% of Jupiter Neurosciences shares are held by company insiders. Comparatively, 13.4% of shares of all “MED – DRUGS” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Jupiter Neurosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-202.57%
Jupiter Neurosciences Competitors	-22,655.91%	-151.34%	-22.75%

Summary

Jupiter Neurosciences peers beat Jupiter Neurosciences on 9 of the 13 factors compared.

About Jupiter Neurosciences

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.